- Home
- GBCI vs TNGX Comparison
GBCI vs TNGX Comparison
Compare GBCI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBCI | TNGX |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.1B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GBCI | TNGX |
|---|---|---|
| Price | $51.98 | $30.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $54.00 | $21.78 |
| AVG Volume (30 Days) | 1.2M | ★ 6.5M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | 18.45 | ★ 26.89 |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $31.52 | N/A |
| Revenue Next Year | $8.46 | N/A |
| P/E Ratio | $83.38 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $39.90 | $5.60 |
| 52 Week High | $53.99 | $34.39 |
Technical Indicators
Market Signals| Indicator | GBCI | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 55.92 |
| Support Level | $47.29 | $19.74 |
| Resistance Level | $53.99 | $34.39 |
| Average True Range (ATR) | 1.19 | 1.94 |
| MACD | 0.23 | -0.28 |
| Stochastic Oscillator | 81.39 | 39.02 |
Price Performance
Historical ComparisonAbout GBCI Glacier Bancorp Inc.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services through its wholly owned bank subsidiary, Glacier Bank. The group provides a full range of banking services to individuals, small to medium-sized businesses, community organizations, and public entities from several locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, Nevada, and Texas. It offers various banking products and services, including: retail banking, business banking, real estate, commercial, agriculture, and consumer loans; and mortgage origination and loan servicing services, among others.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.